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Anemia is a common problem in intensive care unit (ICU)
patients. Included among the numerous factors that may con-
tribute to the development of anemia in critically ill patients
are the following.
• Frequent blood sampling for measurements of arterial
blood gases and other laboratory parameters.
• Clinically apparent and/or occult blood loss from the
gastrointestinal tract due to erosive gastrointestinal
mucosal disease or tissue trauma caused by suctioning of
gastric contents.
• Blood loss at the time of surgical procedures preceding
admission to the ICU.
• Blood loss due to trauma preceding admission to the ICU.
• Inappropriately low circulating concentrations of erythro-
poietin (EPO) [1–6], the main humoral regulator of red
blood cell (RBC) production.
• Diminished responsiveness of bone marrow precursor cells
to EPO, for example due to decreased availability of iron.
Erythropoietin is a glycoprotein that regulates RBC produc-
tion by modulating the survival and proliferation of erythroid
colony-forming units in the bone marrow. Diminished tissue
oxygen tension is the primary stimulus for EPO release, and in
humans, the kidney is the main organ responsible for EPO
production. Tissue oxygen tension is thought to regulate EPO
production via an oxygen-responsive transcription factor
called hypoxia-inducible factor (HIF)-1 [7]. First identified by
Semenza and Wang [8], HIF-1 is a heterodimeric transcrip-
tion factor composed of a hypoxia-inducible HIF-1α chain and
a constitutively expressed HIF-1β chain. Although mRNA for
HIF-1α is expressed at relatively high levels in normoxic cells,
HIF-1α protein is present at extremely low levels under these
conditions. In normoxic cells, newly synthesized HIF-1α is
subjected to polyubiquitination and targeted for degradation
in proteosomes. Thus, the half-life for this protein is very short,
and its concentration under normoxic conditions is low.
However, when cells become hypoxic, polyubiquitinization of
nascent HIF-1α decreases, and cytosolic levels of this protein
increase. HIF-1α combines with HIF-1β to form the fully func-
tional transcription factor, which is capable of binding to cis-
acting regulatory elements in a number of hypoxia-responsive
genes, including the gene for EPO. A phosphorylation event
also may be important in the regulation of HIF-1 activity.
Numerous clinical studies support the notion that the EPO
response to anemia is blunted in critical illness. Rogiers and
coworkers [4] took serial measurements of serum EPO levels
in 36 critically ill adults. Eighteen ambulatory patients with
iron-deficiency anemia served as a control group. As
expected, a significant inverse correlation between hemato-
crit values and EPO levels was observed in the control indi-
viduals (r = –0.81; P < 0.001). However, no such correlation
was apparent for the critically ill patients (r = –0.09; P = NS).
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Abstract
The formation of red blood cells (RBCs) in the bone marrow is regulated by erythropoietin in response
to a cascade of events. Anemia in the intensive care unit can be caused by a host of factors. Patients in
the intensive care unit may have decreased RBC production and a blunted response to erythropoietin.
Administration of recombinant human erythropoietin may stimulate erythropoiesis, increase hematocrit
levels and hemoglobin concentration, and reduce the need for RBC transfusions.
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Krafte-Jacobs and coworkers [5] conducted a similar study,
but they evaluated EPO levels in critically ill pediatric patients
instead of adults. In 21 acutely anemic critically ill patients,
the mean hemoglobin concentration was 7.8 ± 1.5 g/dl and
the mean EPO level was 39 ± 62 mU/ml. In comparison, the
mean hemoglobin concentration in 21 chronically anemic
patients was 7.3 ± 1.3 g/dl and the mean EPO level was
861 ± 758 mU/ml. Similar findings were obtained in a third
study conducted by Von Ahsen and coworkers [6]. Studying
patients in a medical ICU, those investigators also found that
EPO levels were inappropriately low for the degree of anemia
in critically ill adults. In addition, they found that iron defi-
ciency (plasma transferrin saturated <20%) is also common
in critically ill patients. Inappropriately low EPO levels persist
for the duration of critical illness [3].
Although endogenous EPO levels tend to be low in ICU
patients, these patients appear to retain their responsiveness
to the hormone. Three randomized prospective trials [9–11]
documented that administration of recombinant human ery-
thropoietin (rHuEPO) can stimulate reticulocytosis and
increase circulating hemoglobin concentration in critically ill
adults. Those studies demonstrated that the cumulative
number of units of packed RBCs transfused was significantly
less in the rHuEPO group than in the placebo group [9–11].
The third study found that patients receiving rHuEPO were
less likely to undergo transfusion [11].
Functional iron deficiency is a major cause for anemia in criti-
cally ill patients and in patients with anemia of chronic
disease [4]. In both groups, laboratory studies typically reveal
low serum iron concentration, low transferrin level, low trans-
ferrin saturation, and elevated serum ferritin concentration;
these findings are consistent with an acute-phase response
and inflammation [1,9,12]. Despite evidence of increased iron
storage, circulating iron concentrations are low, and thus less
free iron is available to support erythropoiesis [13]. Similar
observations have been reported from studies of patients
with multiple organ failure [14], victims of multiple trauma [2],
and patients recovering from major surgery [15].
Low concentrations of vitamin B12 and folic acid, which are
essential for normal RBC development, also might contribute
to ineffective erythropoiesis in critically ill patients. Von Ahsen
and coworkers [6] observed normal vitamin B12 levels but
abnormally low folic acid concentrations in some anemic ICU
patients. RBC size was not increased, and therefore the sig-
nificance of folic acid deficiency as a factor contributing to
ICU-acquired anemia remains uncertain. Recently, Rodriguez
and colleagues reported iron deficiency in 9% of ICU patients
[1]; 2% of the patients were deficient in vitamin B12, and
another 2% suffered from folic acid deficiency.
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